A Double-Blind Placebo-Controlled Study of the Effects of the Bisphosphonate Risedronate on Bone Mass in Patients with Inflammatory Bowel Disease

BACKGROUND:Low bone density and fractures are common in patients with inflammatory bowel disease (IBD).OBJECTIVE:To determine whether the bisphosphonate risedronate and calcium are safe and effective in preserving bone mass compared to calcium alone in IBD patients with low bone mass.PATIENTS:Sixty-one ambulatory patients with Crohn's disease (n = 31) or ulcerative colitis (n = 30) and low bone density.METHODS:Using a double-blind placebo-controlled trial format, patients were randomized to 12 months of therapy with risedronate 5 mg or placebo. All received a 600 mg calcium supplement. Bone density using dual energy X-ray absorptiometry was performed at baseline and at 12 months. Disease activity, use of corticosteroid, and adverse events were noted.RESULTS:Forty-eight patients completed the trial. Compared to the placebo group risedronate resulted in a 2.0% (95%CI, 0.02–3.97) and 1.9% (95%CI, 0.21–3.62) improvement in bone density at the spine and hip, respectively. IBD diagnosis, gender, therapy, and disease status had no effect on the results. There were no significant differences in the adverse events.CONCLUSIONS:Risedronate improved bone density at the spine and hip in patients with either Crohn's disease or ulcerative colitis and low bone mass. These data suggest that risedronate is a safe and effective therapy to improve bone mass in these patients.

[1]  M. Dougados,et al.  Bone loss in patients with inflammatory bowel disease: A prospective study , 1995, Osteoporosis International.

[2]  D. Jaspersen,et al.  [Gastrointestinal side effects of drugs]. , 2004, Deutsche medizinische Wochenschrift.

[3]  W. Kratzer,et al.  Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate , 2003, Alimentary pharmacology & therapeutics.

[4]  R. Lindsay,et al.  Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. , 2002, Mayo Clinic proceedings.

[5]  A. Devine,et al.  Effects of vitamin D metabolites on intestinal calcium absorption and bone turnover in elderly women. , 2002, The American journal of clinical nutrition.

[6]  S. Dhaliwal,et al.  Precision error of fan-beam dual X-ray absorptiometry scans at the spine, hip, and forearm. , 2000, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[7]  M. Staun,et al.  Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. , 2000, Gastroenterology.

[8]  S. Laurberg,et al.  Fracture risk is increased in Crohn's disease, but not in ulcerative colitis , 2000, Gut.

[9]  S. Wallach,et al.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.

[10]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[11]  W. Fries,et al.  Evolution of osteopenia in inflammatory bowel disease , 1999, American Journal of Gastroenterology.

[12]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[13]  Z. Tulassay,et al.  Altered Bone Metabolism in Inflammatory Bowel Disease , 1998, American Journal of Gastroenterology.

[14]  Jacques P. Brown,et al.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. , 1998, The New England journal of medicine.

[15]  I. Forgacs,et al.  Reduced bone density in patients with inflammatory bowel disease. , 1997, Gut.

[16]  M. Manns,et al.  Altered bone metabolism in inflammatory bowel disease. , 1997, The American journal of gastroenterology.

[17]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[18]  C. Bernstein,et al.  A randomized, placebo‐controlled trial of calcium supplementation for decreased bone density in corticosteroid‐using patients with inflammatory bowel disease: a pilot study , 1996, Alimentary pharmacology & therapeutics.

[19]  R. Prince,et al.  Comparison of biochemical markers of bone turnover in paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross‐links , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  P. Tugwell,et al.  Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. , 1996, The Journal of rheumatology.

[21]  R. Recker,et al.  Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .

[22]  T. Karttunen,et al.  A controlled study of bone mineral density in patients with inflammatory bowel disease. , 1995, Gut.

[23]  Deborah Kerr,et al.  The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  P. Ferenci,et al.  Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. , 1995, European journal of gastroenterology & hepatology.

[25]  M. Dougados,et al.  Metabolic bone assessment in patients with inflammatory bowel disease. , 1995, Gastroenterology.

[26]  J. Sayre,et al.  Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  D. Clements,et al.  Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. , 1993, Gut.

[28]  R. Prince,et al.  Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. , 1992, Nephron.

[29]  W. Mysiw,et al.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[30]  R. Devlin,et al.  Human lactation: Forearm trabecular bone loss, increased bone turnover, and renal conservation of calcium and inorganic phosphate with recovery of bone mass following weaning , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  J. Compston,et al.  Osteoporosis in patients with inflammatory bowel disease. , 1987, Gut.

[32]  P. Price,et al.  Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. , 1980, Proceedings of the National Academy of Sciences of the United States of America.